<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869778</url>
  </required_header>
  <id_info>
    <org_study_id>71006.01</org_study_id>
    <nct_id>NCT00869778</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) in Treating Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Jiachen Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chongqing Jiachen Biotechnology Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus（HBV） vaccine
      (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective
      dosage and provide the rational for optimal dosing schedule.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First stage(0-76 weeks):

      Eligible subjects are enrolled and assigned to 3 groups randomly in a 1:1:1 ratio：

        1. εPA-44 600μg group：Subcutaneous inject εPA-44 600μg at week 0, 4, 8, 12, 20, 28；Polyene
           Phosphatidylcholine Capsules will be taken orally beginning in week 28.

        2. εPA-44 900μg group：Subcutaneous inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28；Polyene
           Phosphatidylcholine Capsules will be taken orally beginning in week 28.

        3. Placebo control group：Subcutaneous inject empty liposome at week 0, 4, 8, 12, 20,
           28；Polyene Phosphatidylcholine Capsules will be taken orally beginning in week 28.

      The study cycle consists of screening and enrollment period (week -6-0), treatment period
      (week 0-28) and follow-up period (week 28-76).

      Second stage(76-144 weeks):

      In this follow-up stage the trial is open designed, and all the subjects completed the first
      stage study(0-76 weeks):

        1. Subjects with no virological response and no serological response in the first stage ,
           and refuse to continue the this follow-up study, will be provided domestic Adefovir
           Dipivoxil for one year freely;

        2. Subjects with virological response but no serological response/with serological response
           but no virological response/neither virological nor serological response in the first
           stage, and be willing to continue the this follow-up study, will be treated by εPA-44
           900 μg；

        3. Subjects with both virological and serological response, will be followed-up to 144
           weeks with no Adefovir Dipivoxil or εPA-44 900 μg treatment.

      The definition of response is defined as below:

        1. Virological response: HBV DNA＜2.93×10∧3IU/ml at 76 weeks;

        2. Serological response: serological conversion of HBeAg at 76 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With HBeAg Seroconversion at Endpoint .</measure>
    <time_frame>Endpoint(LOCF), up to 76 Weeks</time_frame>
    <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HBeAg Seroconversion at Weeks 12, 28, 32, 40, 52, 64, 76</measure>
    <time_frame>serology response at week 12, 28, 32, 40, 52, 64, 76</time_frame>
    <description>HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Serum HBV DNA Load Decrease Equal or Greater Than 1 Log Scale;</measure>
    <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 12,28,32,40,52,64,76</measure>
    <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Both Negative HBeAg and HBeAb;</measure>
    <time_frame>at week 12, 28, 32, 40, 52, 64, 76.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Positive Anti-HBe</measure>
    <time_frame>at week 12, 28, 32, 40, 52, 64, 76.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline by Visit for HBeAg Titer</measure>
    <time_frame>at week 12, 28, 32, 40, 52, 64, 76.</time_frame>
    <description>Measuring the change in value of each visit viewpoints HBeAg titers decreased compared with baseline values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Serum HBV DNA Load Decrease Equal or Greater Than 2 Log Scale;</measure>
    <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Patients With Serum HBV DNA Level &lt; 29300 IU / ml;</measure>
    <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline by Visit for Serum HBV DNA</measure>
    <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
    <description>Measuring the change in value of each visit viewpoints HBV DNA titers decreased compared with baseline values</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">360</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>εPA-44 900μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>εPA-44 600μg+Placebo 300μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 900μg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>εPA-44</intervention_name>
    <description>subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.</description>
    <arm_group_label>εPA-44 900μg</arm_group_label>
    <arm_group_label>εPA-44 600μg+Placebo 300μg</arm_group_label>
    <other_name>Therapeutic HBV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.</description>
    <arm_group_label>εPA-44 600μg+Placebo 300μg</arm_group_label>
    <arm_group_label>Placebo 900μg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18-65 years, male or female

          2. Conforms to diagnosis standard of chronic hepatitis B according to&quot;2005 Guideline for
             Prevention and Treatment of Hepatitis B&quot;, (with positive HBsAg for more than 6
             months), and HBV-DNA more than 100000 copies/ml;HBeAg (+),HBsAb(-); Alanine
             aminotransferase（ALT） within 2 to 10 times of ULN (upper limit of normal)

          3. HLA-A2 positive

          4. Compensatory liver disease having following hematological and biochemical
             indicators:WBC≥3.5E+9/L; ANC≥1.5E+9/L; PLT≥80E+9/L; Hb≥110g/L; TBil≤1.5ULN; ALB ≥
             lower limit of normal value; BUN (Urea)≤upper limit of normal value; Cr≤upper limit of
             normal value; prothrombin time(PT) elongation≤3 sec; Activated partial thromboplastin
             time（APTT） within normal value; Fasting blood glucose≤7.0mmol/L

          5. TSH within normal value

          6. AFP ≤20ng/ml

          7. Uses effective contraception for subject with child-bearing potential (including
             females and female partners of males)

          8. Understands and signs ICF approved by EC

          9. Willing to comply with the study procedures and complete the study

        Exclusion Criteria:

          1. Antibody of HAV IgM, HCV, HDV IgM or HEV IgM is positive

          2. Antibody of CMV IgM, EBV IgM or HIV is positive

          3. Antinuclear antibody titer＞1:160

          4. Hepatocarcinoma, suspected hepatocarcinoma or hepatic cirrhosis

          5. Has any of the following illnesses or has a severe disease inappropriate for
             participation in the study based on the investigator's judgment, such as:
             Cardiovascular system: instable or significant cardiovascular illness such as angina
             pectoris, heart attack of myocardial infarction, congestive heart failure, severe
             hypertension, significant arrhythmia or abnormal ECG etc.; Respiratory system:
             bronchiectasis, bronchial asthma, chronic obstructive pulmonary disease, respiratory
             failure, etc.; Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid
             diseases, etc.; Others: autoimmune disorder, active tuberculosis, malignancies
             (e.g.tumor), neuropathic or metal illness history,etc.

          6. Has used anti-HBV drug (Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and
             Telbivudine) and immunomodulator (Thymic peptide,etc ) 6 months prior to the
             administration of study medication

          7. Has participated in any other drug clinical investigations within the past 3 months

          8. Has allergy habitus or has suspected allergy to study drug

          9. Female who is in pregnancy, in lactation or planning to become pregnant during the
             course of the study

         10. Has a history of alcohol abuse (Alcohol consumption for more than 5 years, with daily
             consumption over 40g for males and over 20g for females) and known drug dependence

         11. Has a history of organ transplant (except external corneal transplantation and hair
             transplantation)

         12. Any other factors inappropriate for enrollment in the study or study completion in the
             view of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lai Wei, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hepatitis Institute of Peking University People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The PLA Beijing Military General Hospital</name>
      <address>
        <city>BeiJing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hosptial of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renmin Hosptial of Wuhan University</name>
      <address>
        <city>WuHan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University</name>
      <address>
        <city>ChangSha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>ChangSha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>81th Hospital of PLA</name>
      <address>
        <city>NanJing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jilin University First Hospital</name>
      <address>
        <city>ChangChun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'An JiaoTong University</name>
      <address>
        <city>Xi'An</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TangDu Hospital</name>
      <address>
        <city>XiAn</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital,SiChuan University</name>
      <address>
        <city>ChengDu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>WenZhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Militray Hosptial of China</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepatitis Institute of Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital</name>
      <address>
        <city>ChongQing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <results_first_submitted>November 20, 2016</results_first_submitted>
  <results_first_submitted_qc>November 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 18, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis B</keyword>
  <keyword>HBeAg positive</keyword>
  <keyword>Therapeutic HBV Vaccine</keyword>
  <keyword>HBV-specific Cytotoxic T Lymphocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 15 sites in the China. The first participant was screened on 26 March 2009. The last participant observation for the Week 76 analysis was on 09 October 2011</recruitment_details>
      <pre_assignment_details>1218 participants were screened and 360 were randomized; 360 randomized participants received at least one dose of study drug, and comprise the Safety Analysis Set and the Full Analysis Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>εPA-44 900μg</title>
          <description>Subcutaneous injection of εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
        </group>
        <group group_id="P2">
          <title>εPA-44 600μg</title>
          <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
        </group>
        <group group_id="P3">
          <title>Placebo 900μg</title>
          <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unblinding</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS</population>
      <group_list>
        <group group_id="B1">
          <title>εPA-44 900μg</title>
          <description>Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
εPA-44: Inject εPA-44 900μg/600μg at week 0, 4, 8, 12, 20, 28.</description>
        </group>
        <group group_id="B2">
          <title>εPA-44 600μg+Placebo 300μg</title>
          <description>Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
εPA-44: Inject εPA-44 900μg/600μg at week 0, 4, 8, 12, 20, 28.
Placebo: Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
        </group>
        <group group_id="B3">
          <title>Placebo 900μg</title>
          <description>Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
Placebo: Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
            <count group_id="B2" value="120"/>
            <count group_id="B3" value="120"/>
            <count group_id="B4" value="360"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" spread="7.28"/>
                    <measurement group_id="B2" value="26.9" spread="8.56"/>
                    <measurement group_id="B3" value="27.4" spread="7.30"/>
                    <measurement group_id="B4" value="26.8" spread="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.92" spread="2.992"/>
                    <measurement group_id="B2" value="21.55" spread="3.004"/>
                    <measurement group_id="B3" value="21.99" spread="2.643"/>
                    <measurement group_id="B4" value="21.74" spread="2.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With HBeAg Seroconversion at Endpoint .</title>
        <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
        <time_frame>Endpoint(LOCF), up to 76 Weeks</time_frame>
        <population>Intention-To-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
εPA-44: Inject εPA-44 900μg/600μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg+Placebo 300μg</title>
            <description>Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
εPA-44: Inject εPA-44 900μg/600μg at week 0, 4, 8, 12, 20, 28.
Placebo: Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
Placebo: Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBeAg Seroconversion at Endpoint .</title>
          <description>Primary endpoint data were summarised under &quot;End of Study&quot;,using the last available post-baseline observation(Last Observation Carried Forward,LOCF)</description>
          <population>Intention-To-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HBeAg Seroconversion at Weeks 12, 28, 32, 40, 52, 64, 76</title>
        <description>HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication</description>
        <time_frame>serology response at week 12, 28, 32, 40, 52, 64, 76</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HBeAg Seroconversion at Weeks 12, 28, 32, 40, 52, 64, 76</title>
          <description>HBeAg seroconversion=HBeAg loss and presence of hepatitis B e antibody (HBeAb). HBeAg is a hepatitis B viral protein and is an indicator of active viral replication</description>
          <population>Intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="7.6"/>
                    <measurement group_id="O3" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="12.6"/>
                    <measurement group_id="O3" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="13.4"/>
                    <measurement group_id="O3" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="20.2"/>
                    <measurement group_id="O3" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Serum HBV DNA Load Decrease Equal or Greater Than 1 Log Scale;</title>
        <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Serum HBV DNA Load Decrease Equal or Greater Than 1 Log Scale;</title>
          <population>Intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="33.6"/>
                    <measurement group_id="O3" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2"/>
                    <measurement group_id="O2" value="48.7"/>
                    <measurement group_id="O3" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="55.5"/>
                    <measurement group_id="O3" value="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.1"/>
                    <measurement group_id="O2" value="55.5"/>
                    <measurement group_id="O3" value="47.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3"/>
                    <measurement group_id="O2" value="53.8"/>
                    <measurement group_id="O3" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3"/>
                    <measurement group_id="O2" value="61.3"/>
                    <measurement group_id="O3" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1"/>
                    <measurement group_id="O2" value="64.7"/>
                    <measurement group_id="O3" value="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 12,28,32,40,52,64,76</title>
        <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 12,28,32,40,52,64,76</title>
          <population>Intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="8.4"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="20.2"/>
                    <measurement group_id="O3" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="29.4"/>
                    <measurement group_id="O3" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="31.9"/>
                    <measurement group_id="O3" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="33.6"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3"/>
                    <measurement group_id="O2" value="37.8"/>
                    <measurement group_id="O3" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Both Negative HBeAg and HBeAb;</title>
        <time_frame>at week 12, 28, 32, 40, 52, 64, 76.</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Both Negative HBeAg and HBeAb;</title>
          <population>Intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Positive Anti-HBe</title>
        <time_frame>at week 12, 28, 32, 40, 52, 64, 76.</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Positive Anti-HBe</title>
          <population>Intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="27.7"/>
                    <measurement group_id="O3" value="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="34.5"/>
                    <measurement group_id="O3" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="37.0"/>
                    <measurement group_id="O3" value="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline by Visit for HBeAg Titer</title>
        <description>Measuring the change in value of each visit viewpoints HBeAg titers decreased compared with baseline values</description>
        <time_frame>at week 12, 28, 32, 40, 52, 64, 76.</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline by Visit for HBeAg Titer</title>
          <description>Measuring the change in value of each visit viewpoints HBeAg titers decreased compared with baseline values</description>
          <population>Intent-to-treat population</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="1250.38"/>
                    <measurement group_id="O2" value="-460.2" spread="2650.77"/>
                    <measurement group_id="O3" value="-278.7" spread="1561.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-285.4" spread="1343.17"/>
                    <measurement group_id="O2" value="-725.2" spread="2774.22"/>
                    <measurement group_id="O3" value="-450.3" spread="1673.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-339.3" spread="1442.08"/>
                    <measurement group_id="O2" value="-768.3" spread="2778.79"/>
                    <measurement group_id="O3" value="-471.3" spread="1692.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-407.4" spread="1523.68"/>
                    <measurement group_id="O2" value="-737.6" spread="2944.83"/>
                    <measurement group_id="O3" value="-496.8" spread="1721.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-410.0" spread="1637.26"/>
                    <measurement group_id="O2" value="-788.0" spread="3015.94"/>
                    <measurement group_id="O3" value="-458.9" spread="1791.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-271.8" spread="1267.02"/>
                    <measurement group_id="O2" value="-822.8" spread="3124.94"/>
                    <measurement group_id="O3" value="-563.4" spread="1800.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-327.5" spread="1286.44"/>
                    <measurement group_id="O2" value="-947.4" spread="3231.94"/>
                    <measurement group_id="O3" value="-629.3" spread="1846.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Serum HBV DNA Load Decrease Equal or Greater Than 2 Log Scale;</title>
        <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Serum HBV DNA Load Decrease Equal or Greater Than 2 Log Scale;</title>
          <population>Intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="19.3"/>
                    <measurement group_id="O3" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4"/>
                    <measurement group_id="O2" value="33.6"/>
                    <measurement group_id="O3" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                    <measurement group_id="O2" value="40.3"/>
                    <measurement group_id="O3" value="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4"/>
                    <measurement group_id="O2" value="47.9"/>
                    <measurement group_id="O3" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="48.7"/>
                    <measurement group_id="O3" value="40.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Patients With Serum HBV DNA Level &lt; 29300 IU / ml;</title>
        <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>The Proportion of Patients With Serum HBV DNA Level &lt; 29300 IU / ml;</title>
          <population>Intent-to-treat population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="17.6"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6"/>
                    <measurement group_id="O2" value="20.2"/>
                    <measurement group_id="O3" value="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="26.9"/>
                    <measurement group_id="O3" value="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="31.1"/>
                    <measurement group_id="O3" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2"/>
                    <measurement group_id="O2" value="32.8"/>
                    <measurement group_id="O3" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline by Visit for Serum HBV DNA</title>
        <description>Measuring the change in value of each visit viewpoints HBV DNA titers decreased compared with baseline values</description>
        <time_frame>week 12, 28, 32, 40, 52, 64, 76</time_frame>
        <population>Intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>εPA-44 900μg</title>
            <description>Participants subcutaneous injected εPA-44 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O2">
            <title>εPA-44 600μg</title>
            <description>Participants subcutaneous injected εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
          <group group_id="O3">
            <title>Placebo 900μg</title>
            <description>Participants subcutaneous injected Placebo 900μg at week 0, 4, 8, 12, 20, 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline by Visit for Serum HBV DNA</title>
          <description>Measuring the change in value of each visit viewpoints HBV DNA titers decreased compared with baseline values</description>
          <population>Intent-to-treat population</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-176000000" spread="927000000"/>
                    <measurement group_id="O2" value="-336000000" spread="1195000000"/>
                    <measurement group_id="O3" value="-129000000" spread="293200000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-213000000" spread="919000000"/>
                    <measurement group_id="O2" value="-362000000" spread="1217000000"/>
                    <measurement group_id="O3" value="-172000000" spread="299000000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-226000000" spread="925700000"/>
                    <measurement group_id="O2" value="-372000000" spread="1218000000"/>
                    <measurement group_id="O3" value="-172000000" spread="308500000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-229000000" spread="917000000"/>
                    <measurement group_id="O2" value="-387000000" spread="1236000000"/>
                    <measurement group_id="O3" value="-181000000" spread="322700000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-219000000" spread="917500000"/>
                    <measurement group_id="O2" value="-373000000" spread="1263000000"/>
                    <measurement group_id="O3" value="-140000000" spread="311600000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-229000000" spread="932100000"/>
                    <measurement group_id="O2" value="-362000000" spread="1045000000"/>
                    <measurement group_id="O3" value="-168000000" spread="340500000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-276000000" spread="870500000"/>
                    <measurement group_id="O2" value="-408000000" spread="1303000000"/>
                    <measurement group_id="O3" value="-207000000" spread="350200000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events After Dosing（0-76week）</time_frame>
      <group_list>
        <group group_id="E1">
          <title>εPA-44 900μg</title>
          <description>Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
εPA-44: Inject εPA-44 at week 0, 4, 8, 12, 20, 28.</description>
        </group>
        <group group_id="E2">
          <title>εPA-44 600μg+Placebo 300μg</title>
          <description>Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
εPA-44: Inject εPA-44 at week 0, 4, 8, 12, 20, 28.
Placebo: Inject Placebo at week 0, 4, 8, 12, 20, 28.</description>
        </group>
        <group group_id="E3">
          <title>Placebo 900μg</title>
          <description>Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
Placebo: Inject Placebo at week 0, 4, 8, 12, 20, 28.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute gastric perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Exacerbation of chronic hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Abnormal liver function</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Acute exacerbation of hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right leg fibula fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mediastinal bronchogenic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Upper abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Right upper quadrant pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Female genital infections</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Coughing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Local injection site reactions</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators can't publish articles relevant to the study unless the sponsor permits.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Wu</name_or_title>
      <organization>Institute of Immunology，PLA</organization>
      <phone>02368752230 ext 86</phone>
      <email>wuyuzhang@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

